8-K: Cullinan Therapeutics Announces Positive Phase 2b Results and Provides Corporate Update

Cullinan Therapeutics reports positive Phase 2b results for zipalertinib and anticipates initial clinical data for CLN-978 in SLE in Q4 2025, with a cash runway into 2028.

Summary

• Cullinan Therapeutics announced its fourth quarter and full year 2024 financial results.
• The company's cash and investments totaled $606.9 million as of December 31, 2024, providing a cash runway into 2028.
• The pivotal Phase 2b study of zipalertinib met its primary endpoint, with full results expected mid-year 2025 and an NDA submission planned for the second half of 2025.
• Initial clinical data from the Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) is expected in Q4 2025.
• Research and development expenses were $40.5 million for the fourth quarter of 2024 and $142.9 million for the full year 2024.
• General and administrative expenses were $14.6 million for the fourth quarter of 2024 and $54.0 million for the full year 2024.
• Net loss attributable to Cullinan was $47.6 million for the fourth quarter of 2024 and $167.4 million for the full year 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong cash reserves and promising clinical trial results, although increased losses temper the overall sentiment.

Positives

• The company has a strong cash position of $606.9 million, providing a cash runway into 2028.
• The pivotal Phase 2b study of zipalertinib met its primary endpoint.
• CLN-978 is the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.
• The company is expanding its clinical trial sites in the United States, Europe, and Australia.

Negatives

• The net loss attributable to Cullinan was $47.6 million for the fourth quarter of 2024, compared to $23.8 million for the same period in 2023.
• The net loss attributable to Cullinan was $167.4 million for the full year 2024, compared to $153.2 million for the full year 2023.

Risks

• The company faces risks related to the timing and results of regulatory submissions.
• There are risks related to the success of clinical trials and preclinical studies.
• The company faces risks related to its ability to protect and maintain its intellectual property position.
• There are risks related to manufacturing, supply, and distribution of product candidates.
• The results of preclinical studies or clinical studies may not be predictive of future results.
• The success of any collaboration, partnership, license or similar agreements is uncertain.

Future Outlook

Cullinan expects its cash resources to provide runway into 2028 based on its current operating plan and anticipates key updates for CLN-978 and zipalertinib in 2025.

Management Comments

• Building on our execution throughout 2024, we are positioned to again deliver meaningful catalysts in 2025, starting with key updates for CLN-978 and zipalertinib, said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics.
• We have established an important competitive advantage in the immunology space as CLN-978 remains the first and only development-stage CD19 T cell engager with U.S. Food and Drug Administration (FDA) IND clearance in autoimmune diseases.
• We are further strengthening our leadership position by rapidly expanding our site footprint and preparing to deliver initial clinical data in SLE in the fourth quarter of 2025.
• For zipalertinib, we recently announced that the pivotal Phase 2b portion of the REZILIENT1 study met the primary endpoint of overall response rate.
• This milestone marks a significant achievement for Cullinan, our partner, Taiho, and most importantly, patients with EGFR exon20 insertion mutation NSCLC who have received prior therapy.
• Together with Taiho, we look forward to discussing next steps with the U.S. FDA and expect to submit an NDA in the second half of 2025.

Industry Context

Cullinan's focus on modality-agnostic targeted therapies in oncology and immunology aligns with the broader industry trend towards personalized medicine and innovative treatment approaches. The company's CLN-978 program in autoimmune diseases positions it as a potential leader in this emerging area.

Comparison to Industry Standards

• Cullinan's cash runway into 2028 provides a significant advantage compared to many smaller biotech companies that often require frequent capital raises.
• The positive Phase 2b results for zipalertinib are encouraging, but the ultimate success will depend on the FDA's review and the drug's performance in the market against competitors like Amgen's Rybrevant.
• The development of CLN-978 as a CD19 T cell engager for autoimmune diseases is a novel approach, but its clinical efficacy and safety will need to be demonstrated in larger trials.

Stakeholder Impact

• Shareholders: Positive results and strong cash position could lead to increased investor confidence.
• Patients: Potential for new treatment options for EGFR ex20ins NSCLC and autoimmune diseases.
• Employees: Continued investment in R&D and clinical trials provides job security and growth opportunities.
• Partners: Collaboration with Taiho Oncology on zipalertinib development.

Next Steps

• Share full results of the zipalertinib pivotal Phase 2b study mid-year 2025.
• Submit an NDA for zipalertinib in the second half of 2025, pending regulatory discussions.
• Initiate a Phase 1 study in rheumatoid arthritis (RA) in the second quarter of 2025.
• Report initial data for CLN-619 in endometrial and cervical cancers in the second quarter of 2025.
• Share initial clinical data from the Phase 1 study of CLN-978 in SLE in Q4 2025.

Key Dates